NOVONIX Ltd Files 6-K, Director Departs
Ticker: NVNXF · Form: 6-K · Filed: Apr 19, 2024 · CIK: 1859795
| Field | Detail |
|---|---|
| Company | Novonix LTD (NVNXF) |
| Form Type | 6-K |
| Filed Date | Apr 19, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-departure, corporate-filing
TL;DR
NOVONIX director out, filing shows.
AI Summary
NOVONIX Ltd filed a Form 6-K on April 19, 2024, reporting an Appendix 3Z filing, which indicates a director's cessation of office. This filing pertains to the month of April 2024 and is submitted under the 1934 Securities Exchange Act.
Why It Matters
This filing signals a change in the company's board of directors, which could impact governance and strategic direction.
Risk Assessment
Risk Level: low — A director's departure is a routine corporate event and does not inherently indicate significant financial or operational risk.
Key Players & Entities
- NOVONIX Ltd (company) — Registrant
- April 19, 2024 (date) — Filing Date
- Appendix 3Z (document) — Filed Exhibit
FAQ
What type of filing is NOVONIX Ltd submitting?
NOVONIX Ltd is submitting a Form 6-K, which is a Report of Foreign Private Issuer.
What is the accession number for this filing?
The accession number for this filing is 0000950170-24-045725.
What is the primary purpose of the Appendix 3Z mentioned in the filing?
The Appendix 3Z filing indicates a director's cessation of office.
Under which act is this Form 6-K filed?
This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What is NOVONIX Ltd's principal executive office address?
NOVONIX Ltd's principal executive office is located at Level 38, 71 Eagle Street, Brisbane, QLD 4000, Australia.
Filing Stats: 241 words · 1 min read · ~1 pages · Grade level 12.8 · Accepted 2024-04-19 09:09:46
Filing Documents
- nvx-6k-apr-24-04-18-app3.htm (6-K) — 20KB
- nvx-ex99_1.htm (EX-99.1) — 33KB
- nvx-ex99_2.htm (EX-99.2) — 71KB
- nvx-ex99_3.htm (EX-99.3) — 83KB
- nvx-ex99_4.htm (EX-99.4) — 85KB
- img59892534_0.jpg (GRAPHIC) — 1KB
- img60816055_0.jpg (GRAPHIC) — 1KB
- img61739576_0.jpg (GRAPHIC) — 1KB
- 0000950170-24-045725.txt ( ) — 298KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVONIX LIMITED By: /s/ Dr. John Christopher Burns Dr. John Christopher Burns Chief Executive Officer Date: April 19, 2024